top of page

AbbVie lines up a new preclinical R&D alliance with the dealmakers at natural killer player

  • maura169
  • Nov 20, 2019
  • 1 min read

Bill Haney is building on his rep as one of the most prolific dealmakers in preclinical R&D, adding a new alliance for Dragonfly Therapeutics with AbbVie on cancer drugs as well as autoimmune diseases — a new field for the upstart developer.




 
 
 

Komentarze


DragonflyTherapeutics_Logo_Color_Final_07.09.16.png
Activating the Immune System to Fight Disease
Contact

DRAGONFLY Therapeutics, Inc.
180 3rd Avenue, Sixth Floor

Waltham, MA 02451
United States

1-617-588-0086

Sitemap
  • Twitter
  • LinkedIn

©2024 Dragonfly Therapeutics - All Rights Reserved

bottom of page